A Multi-Center Phase II Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2024 Planned End Date changed from 1 May 2023 to 1 May 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2025.